Zacks Research Equities Analysts Boost Earnings Estimates for Alkermes plc (NASDAQ:ALKS)

Alkermes plc (NASDAQ:ALKS) – Stock analysts at Zacks Research upped their Q1 2025 EPS estimates for shares of Alkermes in a research note issued on Tuesday, June 25th. Zacks Research analyst R. Department now expects that the company will earn $0.41 per share for the quarter, up from their previous forecast of $0.40. The consensus estimate for Alkermes’ current full-year earnings is $2.27 per share. Zacks Research also issued estimates for Alkermes’ FY2025 earnings at $1.90 EPS.

Several other equities research analysts have also recently commented on the company. TD Cowen began coverage on Alkermes in a research note on Monday, June 17th. They issued a “buy” rating and a $34.00 target price for the company. Piper Sandler reiterated an “overweight” rating and issued a $39.00 price objective on shares of Alkermes in a research report on Monday, April 1st. Jefferies Financial Group upped their target price on shares of Alkermes from $42.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, April 9th. StockNews.com cut shares of Alkermes from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. Finally, Robert W. Baird assumed coverage on shares of Alkermes in a research note on Tuesday, March 19th. They set an “outperform” rating and a $37.00 price target for the company. One research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Alkermes currently has a consensus rating of “Moderate Buy” and a consensus price target of $36.50.

Alkermes Stock Performance

ALKS stock opened at $24.10 on Friday. The company has a 50 day moving average price of $24.28 and a 200 day moving average price of $26.57. Alkermes has a fifty-two week low of $22.01 and a fifty-two week high of $32.89. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.20 and a quick ratio of 2.77. The stock has a market capitalization of $4.08 billion, a PE ratio of 9.53, a price-to-earnings-growth ratio of 0.49 and a beta of 0.47.

Alkermes (NASDAQ:ALKS) last announced its earnings results on Wednesday, May 1st. The company reported $0.43 earnings per share for the quarter, missing analysts’ consensus estimates of $0.58 by ($0.15). Alkermes had a return on equity of 20.31% and a net margin of 25.17%. The company had revenue of $350.37 million during the quarter, compared to the consensus estimate of $360.26 million. During the same period in the prior year, the firm posted ($0.10) earnings per share. The company’s revenue was up 21.8% on a year-over-year basis.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ALKS. McGlone Suttner Wealth Management Inc. acquired a new stake in Alkermes in the fourth quarter worth $30,000. GAMMA Investing LLC bought a new stake in shares of Alkermes in the 4th quarter valued at $35,000. Daiwa Securities Group Inc. raised its stake in Alkermes by 166.4% during the 4th quarter. Daiwa Securities Group Inc. now owns 1,761 shares of the company’s stock worth $49,000 after buying an additional 1,100 shares during the period. CWM LLC lifted its holdings in Alkermes by 92.8% during the fourth quarter. CWM LLC now owns 1,999 shares of the company’s stock worth $55,000 after acquiring an additional 962 shares in the last quarter. Finally, Measured Wealth Private Client Group LLC acquired a new position in Alkermes in the fourth quarter valued at about $209,000. Institutional investors and hedge funds own 95.21% of the company’s stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.